Datametrex Announces Private Placement Extension
Datametrex AI (OTCQB:DTMXF) has requested an extension from the TSX Venture Exchange for closing its previously announced non-brokered private placement. The company expects to complete the process and file final documentation by August 11, 2025.
The proceeds will fund the expansion of healthcare product offerings and relocation of two healthcare clinics. The placement may include finders' fees of up to 10% cash and 10% broker warrants. All issued securities will have a four-month and one-day hold period per Canadian securities laws.
Datametrex AI (OTCQB:DTMXF) ha richiesto una proroga alla TSX Venture Exchange per completare la chiusura della sua precedente offerta privata non intermedia. La societ脿 prevede di concludere il processo e depositare la documentazione finale entro il 11 agosto 2025.
I proventi serviranno per espandere l'offerta di prodotti nel settore sanitario e per il trasferimento di due cliniche mediche. L'offerta potrebbe includere commissioni per i promotori fino al 10% in contanti e 10% in warrant per broker. Tutti i titoli emessi saranno soggetti a un periodo di blocco di quattro mesi e un giorno, secondo le leggi canadesi sui valori mobiliari.
Datametrex AI (OTCQB:DTMXF) ha solicitado una pr贸rroga a la TSX Venture Exchange para cerrar su colocaci贸n privada previamente anunciada sin intermediarios. La compa帽铆a espera completar el proceso y presentar la documentaci贸n final antes del 11 de agosto de 2025.
Los fondos se destinar谩n a la expansi贸n de la oferta de productos de salud y a la reubicaci贸n de dos cl铆nicas m茅dicas. La colocaci贸n podr铆a incluir honorarios para los intermediarios de hasta un 10% en efectivo y 10% en warrants para corredores. Todos los valores emitidos tendr谩n un per铆odo de retenci贸n de cuatro meses y un d铆a conforme a las leyes canadienses de valores.
Datametrex AI (OTCQB:DTMXF)電� 鞚挫爠鞐� 氚滍憸頃� 牍勳臧� 靷 氚滍枆 毵堦皭鞚� 鞙勴暣 TSX 氩れ矘 瓯半灅靻岇棎 鞐办灔 鞖旍箔鞚� 頄堨姷雼堧嫟. 須岇偓電� 2025雲� 8鞗� 11鞚�旯岇 鞝堨皑毳� 鞕勲頃橁碃 斓滌 氍胳劀毳� 鞝滌稖頃� 鞓堨爼鞛呺媹雼�.
鞛愱笀鞚� 鞚橂 鞝滍拡 霛检澑 頇曥灔瓿� 霊� 臧滌潣 鞚橂 韥措Μ雼� 鞚挫爠鞐� 靷毄霅� 鞓堨爼鞛呺媹雼�. 鞚措矆 氚滍枆鞐愲姅 斓滊寑 順勱笀 10% 氚� 欷戧皽鞚� 鞗岆煱韸� 10%鞚� 靻岅皽 靾橃垬耄岅皜 韽暔霅� 靾� 鞛堨姷雼堧嫟. 氚滍枆霅� 氇摖 歃濌秾鞚� 旌愲倶雼� 歃濌秾氩曥棎 霐半澕 4臧滌洈 1鞚缄皠鞚� 氤挫湢 旮瓣皠鞚� 鞝侅毄霅╇媹雼�.
Datametrex AI (OTCQB:DTMXF) a demand茅 une prolongation 脿 la TSX Venture Exchange pour finaliser son placement priv茅 non parrain茅 pr茅c茅demment annonc茅. La soci茅t茅 pr茅voit de terminer le processus et de d茅poser la documentation finale d'ici le 11 ao没t 2025.
Les fonds serviront 脿 financer l'expansion de l'offre de produits de sant茅 et le d茅m茅nagement de deux cliniques m茅dicales. Le placement peut inclure des frais de recherche allant jusqu'脿 10% en esp猫ces et 10% en bons de souscription pour courtiers. Tous les titres 茅mis seront soumis 脿 une p茅riode de blocage de quatre mois et un jour conform茅ment aux lois canadiennes sur les valeurs mobili猫res.
Datametrex AI (OTCQB:DTMXF) hat bei der TSX Venture Exchange eine Verl盲ngerung f眉r den Abschluss seiner zuvor angek眉ndigten nicht vermittelten Privatplatzierung beantragt. Das Unternehmen erwartet, den Prozess bis zum 11. August 2025 abzuschlie脽en und die endg眉ltigen Unterlagen einzureichen.
Die Erl枚se werden zur Erweiterung des Angebots an Gesundheitsprodukten und zur Verlegung von zwei Gesundheitskliniken verwendet. Die Platzierung kann Vermittlungsgeb眉hren von bis zu 10% in bar und 10% Broker-Warrants beinhalten. Alle ausgegebenen Wertpapiere unterliegen gem盲脽 kanadischem Wertpapierrecht einer Haltefrist von vier Monaten und einem Tag.
- Funds will be used for healthcare business expansion and clinic relocations
- No new control person will be created from the private placement
- Delay in closing the previously announced private placement
- Potential dilution from the issuance of new securities and broker warrants
TORONTO, ON / / July 8, 2025 / Datametrex AI Limited (the 'Company' or 'Datametrex') (TSXV:DM)(FSE:D4G)(OTCQB:DTMXF) announces that further to its news release of June 9, 2025, the Company has applied to the TSX Venture Exchange for an extension to allow for the closing of its non-brokered private placement with its investors. The Company expects this process to be completed within the next two weeks and intends to file the final documentation no later than August 11, 2025, subject to approval by the Exchange.
The gross proceeds of the Private Placement will be used for expansion of the Company's healthcare product offering, relocation of two healthcare clinics and general working capital.
In connection with the Private Placement, the Company may pay finders' fees up to
The closing of the Private Placement is subject to certain standard conditions including, but not limited to, the acceptance of the TSX Venture Exchange.
All securities that are issued pursuant to the Private Placement will be subject to a hold period of four months and one day in accordance with applicable Canadian securities laws. The Private Placement will not result in the creation of a new control person of the Company.
The securities offered have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold absent registration or compliance with an applicable exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws.
About Datametrex
Datametrex is an innovative leader in Technology Solutions, Artificial Intelligence, Healthcare, and Mobile Gaming. The Company excels in delivering tools and solutions that enhance operational efficiencies and business outcomes. With a commitment to innovation, Datametrex is dedicated to supporting enterprises by setting a new standard for business protocols through cutting-edge technology.
For more on Datametrex, please visit our .
For Additional Information:
Paul Haber, C.P.A., C.A., C.Dir
CEO & Chairman
[email protected]
(416) 318-6501
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains "forward-looking statements," which involve risks, uncertainties, and factors that could cause actual results to differ materially from those anticipated. These statements are not historical facts and are generally identified by words such as "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," and similar expressions. Such statements include expectations related to healthcare business and other Company plans.
While Datametrex believes the forward-looking information is reasonable as of the date of this release, these statements involve assumptions, risks, and uncertainties that could cause actual outcomes to differ. Key factors include general economic conditions, legislative and regulatory developments, access to capital, industry competition, and the Company's ability to execute its strategies. The Company does not undertake to update these statements, except as required by law. Readers are advised not to place undue reliance on forward-looking information.
Factors that could cause actual results to differ materially are detailed under "Risk Factors" in Datametrex's management's discussion and analysis and available on the Company's profile at .
This release does not constitute an offer to sell or a solicitation to buy, nor shall it constitute an offer, solicitation, or sale in any jurisdiction where such would be unlawful prior to registration or qualification under applicable securities laws. We seek Safe Harbor.
SOURCE: DataMetrex AI Ltd.
View the original on ACCESS Newswire
FAQ
What is the purpose of Datametrex (DTMXF) private placement extension?
How will Datametrex (DTMXF) use the private placement proceeds?
What are the terms of Datametrex (DTMXF) private placement finders' fees?
How long is the hold period for securities issued in the Datametrex private placement?
Will the Datametrex private placement create a new control person?
